IPro-CTSm: Prodromes of Menstrual Staphylococcal Toxic Shock

Sponsor
Hospices Civils de Lyon (Other)
Overall Status
Recruiting
CT.gov ID
NCT06124599
Collaborator
(none)
316
1
60
5.3

Study Details

Study Description

Brief Summary

Menstrual staphylococcal toxic shock is a rare but severe disease, requiring intensive care in over 80% of cases. Menstrual staphylococcal toxic shock develops during the peri-menstrual period, in healthy young women colonized by a vaginal strain of Staphylococcus aureus secreting the Toxic shock syndrome toxin 1 (TSST-1) and not immune to it, in a favorable environment, i.e. wearing intravaginal menstrual protection (tampon, menstrual cup).

The rarity of the syndrome, its polymorphous clinical presentation and the absence of a totally specific biological examination make menstrual staphylococcal toxic shock a difficult pathology to diagnose. The reference clinical criteria correspond to the advanced picture of multivisceral failure, making it possible to classify cases a posteriori, but contribute to diagnostic delay and lack sensitivity.

Patient accounts suggest the presence of symptoms in the days preceding the development of toxic shock, and also during previous menstrual cycles.

The identification of prodromal symptoms could enable earlier management of menstrual staphylococcal toxic shock by removal of intra-vaginal sanitary protection, the main risk factor, before the disease becomes permanently established and requires intensive care.

Condition or Disease Intervention/Treatment Phase
  • Other: Identification of symptoms of menstrual staphylococcal toxic shock in last three menstrual period
  • Other: Identification of symptoms of menstrual in control patient in the last three menstrual period

Study Design

Study Type:
Observational
Anticipated Enrollment :
316 participants
Observational Model:
Case-Control
Time Perspective:
Retrospective
Official Title:
Identification of Prodromal Clinical Signs of Menstrual Staphylococcal Toxic Shock
Actual Study Start Date :
Dec 21, 2021
Anticipated Primary Completion Date :
Dec 21, 2026
Anticipated Study Completion Date :
Dec 21, 2026

Arms and Interventions

Arm Intervention/Treatment
Women who have developed menstrual staphylococcal toxic shock

Clinical diagnosis of staphylococcal toxic shock syndrome: "confirmed" or "probable" according to CDC criteria : The 5 CDC clinical criteria for Staphylococcal Toxic Shock are: a fever above 39°C, arterial hypotension, generalized scarlatiniform erythroderma intense desquamation of the palms or soles of the feet 7 to 14 days later, and systemic manifestations (at least three): Digestive: vomiting, diarrhea Muscular: myalgias, increased serum creatine phospho-kinase Vaginal, oropharyngeal and conjunctival mucosal hyperemia Renal: hyperuricemia, hypercreatininemia, leukocyturia without urinary infection, Hepatic: increased transaminases Hematological: thrombocytopenia (< 100,000 platelets/mm3) Neurological: excluding episodes of fever or hypotension such as disorientation or altered consciousness. If 4 criteria are met, the case is considered probable, and if 5 criteria are met, confirmed.

Other: Identification of symptoms of menstrual staphylococcal toxic shock in last three menstrual period
questionnaire including : fever felt or measured; chills; malaise or feeling of malaise (dizziness when standing up); unusual fatigue; headache; confusion, disorientation; nausea; vomiting; diarrhea; abdominal pain; muscle pain, aches; sore throat or pain when swallowing; red tongue or mouth ulceration; skin rashes (redness, patches...); other

Control healthy women

Women over 13 years of age, menstruating and using internal sanitary protection with No history of menstrual toxic shock for controls

Other: Identification of symptoms of menstrual in control patient in the last three menstrual period
questionnaire including : fever felt or measured; chills; malaise or feeling of malaise (dizziness when standing up); unusual fatigue; headache; confusion, disorientation; nausea; vomiting; diarrhea; abdominal pain; muscle pain, aches; sore throat or pain when swallowing; red tongue or mouth ulceration; skin rashes (redness, patches...); other...

Outcome Measures

Primary Outcome Measures

  1. Women with No history of menstrual toxic shock for controls [in the week following the last menstrual period]

    A single collection of information through a questionnaire delivered to the last menstrual period

  2. Patient with Menstrual Staphylococcal Toxic Shock (STC) [in the week following onset Staphylococcal Toxic Shock]

    A single collection of information through a questionnaire delivered as close as possible to the occurrence of the STC

Eligibility Criteria

Criteria

Ages Eligible for Study:
13 Years to 30 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria :

+Case inclusion criteria:

  • Women between 13 and 30 years old inclusive

  • Clinical diagnosis of staphylococcal toxic shock syndrome: "confirmed" or "probable" according to Center Disease Control (CDC) criteria:

The 5 CDC clinical criteria for menstrual Staphylococcal Toxic Shock are:
  • a fever above 39°C,

  • arterial hypotension,

  • generalized scarlatiniform erythroderma

  • intense peeling of the palms or soles of the feet 7 to 14 days later,

  • and systemic manifestations (at least three):

  • Digestive: vomiting, diarrhea

  • Muscular: myalgia, increase in serum creatine phosphokinase

  • Hyperemia of the vaginal, oropharyngeal and conjunctival mucous membranes

  • Renal: hyperuricemia, hypercreatininemia, leukocyturia without urinary infection,

  • Hepatic: increase in transaminases

  • Hematological: thrombocytopenia (< 100,000 platelets/mm3)

  • Neurological: apart from episodes of fever or hypotension such as disorientation or altered consciousness.

In the presence of 4 criteria, the case is considered probable and 5 criteria as confirmed case.

  • Detection of S. aureus strain carrying Toxic shock syndrome toxin-1 (TSST1) on vaginal samples.

  • Onset of symptoms ≤ 72 hours before the start of menstruation and ≥ 72 hours after the end of menstruation.

  • Use during the last 3 cycles of vaginal protection: tampon or menstrual cup.

+Control inclusion criteria:

  • Women between 13 and 30 years old inclusive

  • Presence of menstruation

  • Use of intimate periodic protection, tampon or menstrual cup, during the last 3 periods

  • No history of toxic menstrual shock

Exclusion Criteria:
  • Non-menstruating women

  • Women protected by law

  • Women (or relatives) who oppose the study

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hopital Nord Croix Rousse Lyon France 69004

Sponsors and Collaborators

  • Hospices Civils de Lyon

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Hospices Civils de Lyon
ClinicalTrials.gov Identifier:
NCT06124599
Other Study ID Numbers:
  • 69HCL20_1008
First Posted:
Nov 9, 2023
Last Update Posted:
Nov 9, 2023
Last Verified:
Nov 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Hospices Civils de Lyon
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 9, 2023